Philogen announces publication of best-in-class FAP-targeting small molecule ligand (OncoFAP) in PNASPress Release - 10th World Congress of Melanoma Press Release - Nature Chemistry Press Release - PNAS
Study shows impressive tumor uptake of OncoFAP with unprecedented selectivity against healthy organs.
OncoFAP-based molecules are currently being developed for the imaging and therapy of cancer.
Philogen announces participation to the 10th World Congress of Melanoma
Philogen will give a poster presentation about the phase II study of Daromun (NidlegyTM) for the treatment of non-melanoma skin cancer.
Philogen announces publication of the construction and application of an innovative DNA-encoded chemical library in Nature Chemistry
Study shows the generation of a high-quality stereo- and regiodefined DNA-encoded chemical library.
Identified ligands against tumor-associated antigens can serve as vehicles for pharmacodelivery applications.
Philogen announces its intention to float on the Mercato Telematico Azionario organised and managed by Borsa Italiana S.P.APress Release 01/02/2021 Comunicato Stampa 01/02/2021
Philogen announces the completion of a second interim analysis of its phase III clinical program with NidlegyTM for the treatment of melanomaPress Release 13/01/2021
NidlegyTMwas found to be well-tolerated and 149 out of the anticipated 214 patients have been safely treated.
Data Safety Monitoring Board recommends to continue the study as planned.